EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50%

被引：0
|
作者：
Rizvi, N. [1 ]
Lee, S. [2 ]
Curtis, P. [2 ]
Caldwell, W. [2 ]
Gao, B. [2 ]
Rietschel, P. [2 ]
机构：
[1] Columbia Univ, Med Ctr, New York, NY USA
[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
Anti-PD-1; cemiplimab; REGN2810;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.04-26
引用
收藏
页码：S931 / S932
页数：2
相关论文
共 19 条
  • [1] EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC with PD-L1 ≥50%, a Phase 3 Study
    Rizvi, N.
    Lee, S.
    Curtis, P.
    Caldwell, W.
    Gao, B.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S931 - S931
  • [2] Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1
    Kilickap, S.
    Sezer, A.
    Gumus, M.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R. G.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S125 - S126
  • [3] EMPOWER-Lung 3: Phase 3 Study of Combinations of Cemiplimab and Chemotherapy in First-Line Treatment of Advanced NSCLC
    Gogishvili, M.
    Mobashery, N.
    Makharadze, T.
    Navarro, M.
    Snodgrass, P.
    Chen, H.
    Lowy, I.
    Rietschel, P.
    Lee, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S649 - S649
  • [4] Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study
    Gumus, Mahmut
    Chen, Chieh-, I
    Ivanescu, Cristina
    Kilickap, Saadettin
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Harnett, James
    Mastey, Vera
    Naumann, Ulrike
    Reaney, Matthew
    Konidaris, Gerasimos
    Sasane, Medha
    Brady, Keri J. S.
    Li, Siyu
    Gullo, Giuseppe
    Rietschel, Petra
    Sezer, Ahmet
    CANCER, 2023, 129 (01) : 118 - 129
  • [5] Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3
    Baramidze, A.
    Gessner, C.
    Gogishvili, M.
    Sezer, A.
    Makharadze, T.
    Kilickap, S.
    Gumus, M.
    Li, Y.
    Li, S.
    Salvati, M.
    Pouliot, J. -F.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S316 - S317
  • [6] Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1
    Gumus, M.
    Kilickap, S.
    Sezer, A.
    Bondarenko, I.
    Ozguroglu, M.
    Gogishvili, M.
    He, X.
    Gullo, G.
    Rietschel, P.
    Quek, R. G.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S321 - S321
  • [7] Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%
    Sezer, A.
    Gogishvili, M.
    Bentsion, D.
    Kilickap, S.
    Lowczak, A.
    Gumus, M.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Lee, S.
    Li, S.
    Snodgrass, P.
    Navarro, M.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S638 - S638
  • [8] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial
    Baramidze, Ana
    Makharadze, Tamta
    Gogishvili, Miranda
    Melkadze, Tamar
    Giorgadze, Davit
    Penkov, Konstantin
    Laktionov, Konstantin
    Nemsadze, Gia
    Nechaeva, Marina
    Rozhkova, Irina
    Kalinka, Ewa
    McIntyre, Debra A. G.
    Perez, Javier
    Kaul, Manika
    Quek, Ruben G. W.
    Seebach, Frank
    Rietschel, Petra
    Pouliot, Jean-Francois
    LUNG CANCER, 2024, 193
  • [9] Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
    Makharadze, Tamta
    Gogishvili, Miranda
    Melkadze, Tamar
    Baramidze, Ana
    Giorgadze, Davit
    Penkov, Konstantin
    Laktionov, Konstantin
    Nemsadze, Gia
    Nechaeva, Marina
    Rozhkova, Irina
    Kalinka, Ewa
    Li, Siyu
    Li, Yuntong
    Kaul, Manika
    Quek, Ruben G. W.
    Poulio, Jean-Francois
    Seebach, Frank
    Lowy, Israel
    Gullo, Giuseppe
    Rietschel, Petra
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (06) : 755 - 768
  • [10] Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%
    Liting Wang
    Ye Peng
    Xiaohui Zeng
    Liubao Peng
    Sini Li
    Shuxia Qin
    Xiaomin Wan
    Chongqing Tan
    Advances in Therapy, 2021, 38 : 4354 - 4365
12